CMHC Masterclass CME Information

Return to Meeting Access Page

ACTIVITY TITLE:

CMHC Masterclass: Addressing the NAFLD / NASH Epidemic: Advances in Pathophysiology, Diagnosis and Management

ACTIVITY DATE:

January 8-9, 2021 | Live Online | Eastern Time

TARGET AUDIENCE

US-based healthcare professionals, including endocrinologists, diabetologists, hepatologists, and gastroenterologists as well as registered nurses, nurse practitioners, pharmacists, and dieticians.

PROGRAM OVERVIEW

The increasing rates of obesity, diabetes, and metabolic syndrome in the United States are leading to more cases NAFLD and NASH, which are now being encountered at a greater frequency in clinical practice. NASH can lead to significant morbidity and mortality, including liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC)—in fact, HCC caused by NASH is poised to become the leading cause of liver transplants in the US.

Significant advances have been made in the understanding of NAFLD/NASH pathophysiology, risk factors, and disease progression, leading to newer diagnostic approaches and therapeutic targets. However, navigating these developments is no easy feat--for example, there are now more than 150 clinical trials for NASH. Are we getting closer to a treatment? What does the future look like? What can we do now to treat NASH? Who is responsible for screening and diagnosing?

During this engaging CMHC Masterclass meeting, you will have a chance to hear from and interact with experts in the NASH space across all specialties. The meeting is designed to bring forward cutting-edge perspectives to the diagnosis and management of NAFLD/NASH, as well as highlight multi-disciplinary solutions that are ultimately needed to improve outcomes.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

  • Review NAFLD/NASH pathogenesis, disease progression, and risk factors for disease progression in order to improve the identification of NASH
  • Define current and emerging approaches and tools to diagnose NAFLD and NASH in clinical practice
  • Utilize the current guidelines and recommendations for treatment of NAFLD and NASH in order to optimize patient management
  • List emerging NASH pharmacotherapies that aim to target various metabolic, inflammatory, and fibrotic pathways involved in disease progression.

FACULTY

Please click here to view all faculty listings.

PROGRAM AGENDA

Please click here to view the full agenda.

JOINT ACCREDITATION STATEMENT

 

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and CMHC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

*credit amount subject to change

PHYSICIAN CONTINUING MEDICAL EDUCATION

The Postgraduate Institute for Medicine designates this live activity for a maximum of *5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING PHARMACY EDUCATION

Postgraduate Institute for Medicine designates this continuing education activity for *5.5 contact hour(s) (0.55 CEUs) of the Accreditation Council for Pharmacy Education.

This is an application-based activity. Universal Activity Numbers (UAN) JA4008162-9999-21-2489-L01-P

CONTINUING NURSING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is *5.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING DIETICIAN EDUCATION

This program offers 5.5 CPEUs for dieticians.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

A full listing of faculty disclosures can be downloaded here.

Planners and Managers

The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

REQUEST FOR CREDIT

Learners may earn up to a maximum of 5.5 AMA/ACPE/ANCC/CDR credits. Please complete the evaluation by Monday, January 18, 2021.  Click to Complete the Evaluation (Registration is required before accessing the evaluation). 

For questions regarding the evaluation, please contact cmhc_eval@cardiometabolichealth.org 

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no registration fee for participating and receiving CME/CE credit for this educational activity.

Return to Meeting Access Page